Senz Oncology is a biotechnology company with an oncology focus. We are developing medicines to provide new treatment options to cancer patients.
Our lead product VAL-1000 is being developed to treat patients with leukaemias and other blood cancers.
Senz Oncology will be attending the following conferences:
- JP Morgan 2016, 11-14 January, San Francisco, CA, USA